Skip to main content
All lobbying filings

Evonik Corporation

Evonik Corporation filed a Q4 report for Evonik Corporation on January 20, 2026, reporting $60,000 in lobbying income.

Lobbying for Evonik Corporation · Manufacturer of specialty chemicals

As filed: EVONIK CORPORATION for EVONIK CORPORATION.

All filings by Evonik Corporation · Everything Evonik Corporation has reported

 Filing · LD-2 quarterly report Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
New Jersey

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 7

Issues related to the Administrations tariff actions and related Congressional oversight

Issues related to TSCA reform Issues related to EPA Premanufacturing Notices Issues related to new chemical reviews PFAS/PFOA oversight and regulatory efforts

Oversight of EPA rules and regulations S.623 / H.R.1415 - No IRIS Act Make American Healthy Again (MAHA) GRAS issue

FY26 appropriations actions H.R. 5371/ P.L. 119-37 FY2026 Continuing Appropriations, Agriculture, Leg. Branch & Extensions Act

General issues related to corporate tax

U.S./China ongoing trade issues Issues related to various trade agreement discussions USMCA Review Process

Issues related to the Surface Transportation Board (STB) and rail mergers

 Bills named in this filing 3
  • S. 623
    No IRIS Act of 2025
  • H.R. 1415
    No IRIS Act of 2025
  • H.R. 5371
    Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions …

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem